Exploring Expectation Bias in Parkinson’s Disease Clinical Trials by Comparing Placebo Arm Progression on MDS-UPDRS to a Natural History Dataset (P9-16.010)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the disease progression in newly diagnosed Parkinson’s disease participants in clinical trials compared to those in a natural history dataset.
Compared disease progression of trial participants with a natural history dataset using MDS-UPDRS scores.
Analyzed placebo arm progression to identify patterns and biases in clinical trial data.
Identified significant differences in MDS-UPDRS scores between clinical trial participants and natural history subjects.
Revealed that expectation bias could influence perceived disease progression in clinical trials.

Randomized trial examines disease progression patterns in Parkinson’s disease participants, suggesting critical insights into bias.

To examine patterns in disease progression of newly diagnosed Parkinson’s disease (PD) participants enrolled in clinical trials vs natural history.

No takes yet. Share an insight, caveat, or question.

Potashman et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share